Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105542 | 0.89 | MAPT (0.56) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL23827487 | 0.85 | GAA (0.53) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1564819 | 0.83 | MAPT (0.59) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL27459761 | 0.82 | MAPT (0.60) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL23827442 | 0.81 | ALDH1A1 (0.49) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5099717 | 0.81 | ALDH1A1 (0.50) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5422196 | 0.80 | ALOX15 (0.51) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL27437249 | 0.78 | MEN1 (0.49) | ALOX15ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5555718 | 0.77 | ALDH1A1 (0.62) | ALOX15ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL23827460 | 0.76 | KMT2A (0.50) | ALOX15ALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | ASTRAZENECA AB | 2003-10-09 | — | — | US | disclosed |
| CN-1122037-C | Thieno [2, 3-d ] pyrimidinediones, preparation method and use thereof, and pharmaceutical compositions containing the same | ASTRA PHARMA PROD (GB) | 2003-09-24 | — | — | CN | disclosed |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | ASTRAZENECA AB. | 2002-12-05 | — | — | US | disclosed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| US-6342502-B1 | ANTIASTHMATICS | ASTRAZENECA AB (GB) | 2002-01-29 | — | — | US | disclosed |
| US-6180635-B1 | NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION | ASTRAZENECA UK LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| CN-1264382-A | Novel compounds | ASTRA PHARMA PROD (GB) | 2000-08-23 | — | — | CN | disclosed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | TPMT, TSLP, TYMP | ALOX15 244/4885ALDH1A1 799/4885GAA 2829/4885 |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | TYMP, DPYD, TYMS | ALOX15 1410/4885ALDH1A1 893/4885GAA 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.